Mutant DNA in plasma of lung cancer patients: Potential for monitoring response to therapy

Annals of the New York Academy of Sciences

Volumn 1022, Issue , 2004, Pages 55-60

  Kimura, Tatsuo ^a   Holland, Will S ^a   Kawaguchi, Tomoya ^a   Williamson, Stephen K ^b   Chansky, Kari ^c   Crowley, John J ^c   Doroshow, James H ^d   Lenz, Heinz Josef ^e   Gandara, David R ^a   Gumerlock, Paul H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^c SW Oncology Group Statistical Center ^*  (United States)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

K RAS; Lung cancer; Plasma DNA; Predictive marker

Indexed keywords

CARBOPLATIN; DNA; PACLITAXEL;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CANCER TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DNA EXTRACTION; DRUG RESPONSE; EVALUATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; LUNG NON SMALL CELL CANCER; MUTATIONAL ANALYSIS; NUCLEOTIDE SEQUENCE; ONCOGENE K RAS; PATIENT MONITORING; PHASE 1 CLINICAL TRIAL; PLASMA; POINT MUTATION; POLYMERASE CHAIN REACTION; PREDICTION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SEQUENCE ANALYSIS; SURVIVAL TIME; TUMOR; WILD TYPE;

EID: 3242709323     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1196/annals.1318.010     Document Type: Conference Paper

References (10)

1. GREENLEE, R.T. et al. 2000. Cancer statistics, 2000. Ca - a Cancer J. Clin. 50: 7-33.
2. WESTRA, W.H. et al. 1993. K-ras oncogene activation in lung adenocarcinomas from former smokers. Evidence that K-ras mutations are an early and irreversible event in the development of adenocarcinoma of the lung. Cancer 72: 432-438.
3. SLEBOS, R.J. et al. 1990. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N. Engl. J. Med. 323: 561-565.
4. GRAZIANO, S.L. et al. 1999. Prognostic significance of K-ras codon 12 mutations in patients with resected stage I and II non-small-cell lung cancer. J. Clin. Oncol. 17: 668-675.
5. NELSON, H.H. et al. 1999. Implications and prognostic value of K-ras mutation for early-stage lung cancer in women. J. Natl. Cancer Inst. 91: 2032-2038.
6. LARA, P.N., JR. et al. 2003. Tirapazamine plus carboplatin and paclitaxel in advanced malignant solid tumors: a California Cancer Consortium phase I and molecular correlative study. Clin. Cancer Res. 9: 4356-4362.
7. WILLIAMSON, S.K. et al. 2003. S0003: paclitaxel/carboplatin (PC) v PC + tirapazamine (PCT) in advanced non-small cell lung cancer (NSCLC). A Phase III Southwest Oncology Group (SWOG) Trial. No. 2502. Proc. Am. Soc. Clin. Oncol.
8. KAWAGUCHI, T. et al. 2003. Methods for isolation and genetic analysis of circulating tumor DNA in patient plasma. In Methods in Molecular Medicine: Novel Anticancer Drug Protocols, Vol. 21: 257-262. The Humana Press. Totowa, NJ.
9. LEVI, S. et al. 1991. Multiple K-ras codon 12 mutations in cholangiocarcinomas demonstrated with a sensitive polymerase chain reaction technique. Cancer Res. 51: 3497-3502.
10. RAMIREZ, J.L. et al. 2003. Methylation patterns and K-ras mutations in tumor and paired serum of resected non-small-cell lung cancer patients. Cancer Lett. 193: 207-216.